| Literature DB >> 25210523 |
Hyun Kyung Bae1, Do Kyung Lee1, Jung Hyun Kwon1, Hae Soon Kim1, Sejung Sohn1, Young Mi Hong2.
Abstract
PURPOSE: The incidence of Kawasaki disease (KD) is rare in young infants (less than 3 months of age), who present with only a few symptoms that fulfill the clinical diagnostic criteria. The diagnosis for KD can therefore be delayed, leading to a high risk of cardiac complications. We examined the clinical characteristics and measured the serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels of these patients for assessing its value in the early detection of KD.Entities:
Keywords: Brain natriuretic peptide; Infant; Kawasaki disease
Year: 2014 PMID: 25210523 PMCID: PMC4155180 DOI: 10.3345/kjp.2014.57.8.357
Source DB: PubMed Journal: Korean J Pediatr ISSN: 1738-1061
Demographic and disease characteristic data obtained from patients with Kawasaki disease and control group patients
Fig. 1The mean number of major diagnostic criteria fulfilled by 21 of the 24 patients enrolled in this study (87.5%), who had incomplete Kawasaki disease. The mean number of major diagnostic criteria fulfilled was 2.8±1.4. Five patients (20.8%) presented with only one symptom fulfilling the diagnostic criteria.
Fig. 2Percentage of patients with specific symptoms that fulfilled the diagnostic criteria for Kawasaki disease (KD). The most common symptoms presented by KD patients were erythema at the site of Bacille Calmette-Guerin (BCG) inoculation (70.8%) and skin rash (50.0%).
Laboratory data obtained from patients in the Kawasaki disease and control groups
Values are presented as mean±standard deviation.
Hb, hemoglobin; Hct, hematocrit; WBC, whole blood count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; NT-proBNP, N-terminal pro-brain natriuretic peptide
*P<0.05 significantly different from control group. †Between control and acute phase.
Fig. 3Serum NT-proBNP levels measured in KD patients in the acute phase (ROC curve). A ROC curve was used to display the level of serum NT-proBNP, measured in KD patients in the acute phase. The AUC was 0.900 (P<0.0001). Level A: 1,749 pg/mL with a sensitivity of 84% and a specificity of 100%. Level B: 1,488 pg/mL with a sensitivity of 84% and a specificity of 95%. Level C: 1,395 pg/mL with a sensitivity of 84% and a specificity of 90%. Level D: 1,300 pg/mL with a sensitivity of 88% and a specificity of 85%. Level E: 1,264 pg/mL with a sensitivity of 88% and a specificity of 80%. ROC, receiver operating characteristic; AUC, area under the curve; KD, Kawasaki disease; NT-proBNP, N-terminal pro-brain natriuretic peptide.
Fig. 4Serum NT-proBNP levels in the control group, and in KD patients measured in the acute and subacute phase. Serum NT-proBNP levels in KD patients, measured in the acute phase, was 4,159±3,714 pg/mL. Serum NT-proBNP levels was 957±902 pg/mL in the control group (significantly lower, P<0.05). Serum NT-proBNP levels decreased significantly in the subacute phase of KD (232±173 pg/mL, P<0.05). KD, Kawasaki disease; NT-proBNP, N-terminal pro-brain natriuretic peptide.
Echocardiographic findings in patients in the Kawasaki disease and control groups
KD, Kawasaki disease; MR, mitral regurgitation; TR, tricuspid regurgitation; LCA, left coronary artery; RCA, right coronary artery; EF, ejection fraction.
*P<0.05 significantly different from control group.